Airduo Digihaler (Fluticasone Propion/Salmeterol) Patent Expiration, LOE Window & CMS Spending
Airduo Digihaler (Fluticasone Propion/Salmeterol) by Teva Pharmaceuticals: FDA Orange Book LOE 2041-01-06, 5 AB generics, $791K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Teva Pharmaceuticals |
| FDA Application & Pathway | N208799 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2041-01-06 |
| Orange Book Patents (*PED Extensions) | 14 patents (7 *PED) |
| Active AB-Rated Generic Competitors | 5 |
| 2024 CMS Total Public Spend | $791K |
| 2024 Medicare Part D Spend | $277K |
| 2024 Medicaid Spend | $514K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.